Hormone Receptor and c-ERBB2 Status in Distant Metastatic and Locally Recurrent Breast Cancer

Autor:	Nan Soon Wong, Gary Man-Kit Tse, Philip C.W. Lui, Puay Hoon Tan, Poh Yian Cheok, Pushpalatha K.A. Idirisinghe, Stephanie Fook-Chong, Aye Aye Thike
Rok vydání:	2010
Předmět:	Oncology medicine.medical_specialty Pathology business.industry Estrogen receptor Cancer General Medicine medicine.disease Primary tumor Metastasis Breast cancer Internal medicine Progesterone receptor medicine Breast disease skin and connective tissue diseases Breast carcinoma business
Zdroj:	American Journal of Clinical Pathology. 133:416-429
ISSN:	1943-7722 0002-9173
DOI:	10.1309/ajcpj57flljrxkpv
Popis:	Estrogen receptor (ER), progesterone receptor (PR), and c-ERBB2 (HER2/neu) are therapeutically and prognostically important markers in the management of breast carcinoma. They are not always analyzed in distant metastatic and locally recurrent breast cancers. We compared immunohistochemical expression in a series of primary breast carcinomas with their distant metastases (n = 72) and local recurrences (n = 45) and analyzed the impact of any changes on survival. Discordance rates between primary and metastatic and between primary and locally recurrent lesions, respectively, were 18% (13/72) and 13% (6/45) for ER, 42% (30/72) and 33% (15/45) for PR, and 7% (5/72) and 2% (1/45) for c-ERBB2. There was statistically significant discordance between primary and metastatic PR status (P = .017; κ = 0.201). Among locally recurrent tumors, 15 (33%) of 45 revealed discordance for PR (P = .006; κ = 0.366). We observed a trend for shorter survival among women with ER– metastatic and locally recurrent tumors regardless of the primary tumor ER status. Our findings suggest a benefit for routine evaluation of ER, PR, and c-ERBB2 status in distant metastatic and locally recurrent breast cancer for therapeutic and prognostic purposes. Estrogen receptor (ER), progesterone receptor (PR), and c-ERBB2 (HER2/neu) are therapeutically and prognostically important markers in the management of breast carcinoma. About 60% to 70% of breast carcinomas express ER protein, and these tumors are associated with better prognosis. 1 Detecting ER expression in a tumor depends on physiologic and technical factors, including menopausal status, endocrine therapy, tumor sampling and intratumoral heterogeneity, tissue fixation, method of examination (biochemical, immunohistochemical), and type of antibody used. 2-4
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::faff4c4fc325fa3f5d2229b42c754e27 https://doi.org/10.1309/ajcpj57flljrxkpv Zobrazit plný text záznamu